Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit for the quarter ended 30th September 2022 reported at ₹23.74crore as against net profit of ₹15.04crore inQ1 FY23, growth of 57.85%.
Total Income from operation for the quarter ended September 2022 reported at ₹146.30crore, higher by 12.54% over Q1 FY23total income from operation of ₹130.00crore. EBITDA for the quarter ended September 2022 was reported at ₹34.59crore as compared to ₹23.41crore in Q1 FY23 showing growth of 47.76%.
Total Income from operation in Q2 FY23 at ₹146.30crore, up 12.5% from ₹130.00crore in Q1 FY23; During the year, company got an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products at Cephalosporin plant. Approved dividend of ₹1.50/- per share for the FY21-22 at the 28thAGM held on 30thSep, 2022. Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximize value for all stakeholders in the near to medium term”.
